放射治疗结合EGFR靶向抑制剂的原理、现状及在非小细胞肺癌中的应用前景  

Combining radiotherapy with EGFR inhibitor for NSCLC:principle and present status

作　　者：樊旼[1] 蔡旭伟[1] 谢立簃[1] 傅小龙[1] 蒋国樑[1] 

机构地区：[1]复旦大学附属肿瘤医院放疗科

出　　处：《中国癌症杂志》2007年第1期32-36,共5页China Oncology

摘　　要：放疗增敏作用是提高综合治疗疗效的主要方式。EGFR通路异常激活,酪氨酸激酶(EGFR-TK)活性增强会激活下游信号通路,肿瘤细胞增殖、侵袭、转移和血管生成的生物学特性得到强化,最终促进了肿瘤的发生和进展,且伴有放射抗拒。EGFR靶向抑制剂均具有明确的放射增敏作用,已经在临床中取得了不同程度的成功,并且有望在非小细胞肺癌的治疗中开拓新的领域。Radiosensitization effect is found to be the major mechanism to achieve prolonged survival in many tumors treated by combined chemo-radiation therapy. EGFR is expressed in many normal human tissues, and activation of this proto-oncogene results in overexpression in many types of human tumors. The enhanced activity of the EGFR-TK could contribute to tumorigenesis and tumor progression through the promotion of tumor cell proliferation, survival, invasiveness, and metastasis, as well as through increased angiogenesis. Signal transduction through the EGFR-TK activates several pathways that are thought to contribute to radiation resistance, including cell cycle alterations, decreased apoptosis, and enhanced proliferation. There is considerable evidence that EGFR inhibitors confer a profound radiosensitization effect. EGFR inhibitors have been tested as a radiosensitizer with radiotherapy intensively. Hopefully, this strategy will expand horizon in NSCLC treatment.

关 键 词：放射治疗 表皮生长因子受体 抑制剂 放射增敏 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.55[医药卫生—临床医学]